<DOC>
	<DOCNO>NCT00685022</DOCNO>
	<brief_summary>The purpose study compare safety tolerability levalbuterol HFA meter dose inhaler ( MDI ) versus racemic albuterol HFA MDI .</brief_summary>
	<brief_title>Safety Tolerability Study Levalbuterol HFA Compared Racemic Albuterol HFA Subjects With Asthma</brief_title>
	<detailed_description>A randomized , modified-blind active-controlled multicenter , two-way crossover study HFA levalbuterol ( without use spacer ) subject 12 year age old asthma . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Subject , male female , must least 12 year age time consent . Female subject 1260 year age inclusive must negative serum pregnancy test study start . Women child bear potential must use acceptable method birth control throughout study . Subject must document diagnosis asthma minimum 6 month prior study start . Subject must good health exception reversible airway disease suffer chronic condition might affect respiratory function . Subject must chest Xray one within 12 month prior randomization . Subject must able complete diary card medical event calendar reliably daily basis , understand dose instruction able demonstrate good MDI administration technique . Any minor subject able must parent/legal guardian assist study activity . Female subject pregnant lactating . Subject participate investigational drug study within 30 day prior study start , currently participate another clinical trial . Subject whose schedule prevent start study visit 9 AM . Subject travel commitment study would interfere trial measurement compliance . Subject history hospitalization asthma within 4 week prior study start , schedule inpatient hospitalization , include elective surgery course trial Subject know sensitivity levalbuterol racemic albuterol , excipients contain formulation . Subject use prescription drug albuterol sulfate administration contraindicate . Subject currently diagnose lifethreatening asthma define history asthma episodes require intubation , associate hypercapnia , respiratory arrest , hypoxic seizure within 12 month prior study start . Subject history cancer ( exception : basal cell carcinoma remission ) . Subject hyperthyroidism , diabetes , hypertension , cardiac disease seizure disorder . Subject history substance abuse drug abuse within 12 month precede study start . Subject great 10 pack year history cigarette smoking use tobacco product within 6 month study start . Subject documented history bronchopulmonary aspergillosis form allergic alveolitis . Subject suffer clinically significant upper low respiratory tract infection 3 week prior study start . Subject unstable asthma ; change asthma therapy ; visit Emergency Department hospital worsen asthma within 4 week . Subject staff member relative staff member .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Racemic albuterol</keyword>
</DOC>